SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 22.31 Billion KRW | -81.77% |
| 2022 | 122.45 Billion KRW | -65.52% |
| 2021 | 355.13 Billion KRW | 979.79% |
| 2020 | 32.88 Billion KRW | 124.08% |
| 2019 | 14.67 Billion KRW | 3387.61% |
| 2018 | 420.84 Million KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -13.71 Billion KRW | -429.0% |
| 2024 Q2 | -11.4 Billion KRW | 16.83% |
| 2024 Q3 | -22.31 Billion KRW | -95.61% |
| 2023 Q2 | -15.97 Billion KRW | -11.97% |
| 2023 Q1 | -14.26 Billion KRW | -151.43% |
| 2023 Q3 | 48.39 Billion KRW | 402.9% |
| 2023 Q4 | 4.16 Billion KRW | -91.38% |
| 2023 FY | 22.31 Billion KRW | -81.77% |
| 2022 FY | 122.45 Billion KRW | -65.52% |
| 2022 Q4 | 27.74 Billion KRW | 33.51% |
| 2022 Q3 | 20.77 Billion KRW | -54.95% |
| 2022 Q2 | 46.12 Billion KRW | 65.88% |
| 2022 Q1 | 27.8 Billion KRW | -84.89% |
| 2021 Q1 | 41.92 Billion KRW | 324.41% |
| 2021 FY | 355.13 Billion KRW | 979.79% |
| 2021 Q4 | 183.96 Billion KRW | 140.68% |
| 2021 Q3 | 76.43 Billion KRW | 44.74% |
| 2021 Q2 | 52.81 Billion KRW | 25.97% |
| 2020 FY | 32.88 Billion KRW | 124.08% |
| 2020 Q2 | -2.52 Billion KRW | 49.69% |
| 2020 Q3 | 32.2 Billion KRW | 1374.21% |
| 2020 Q4 | 9.87 Billion KRW | -69.33% |
| 2020 Q1 | -5.02 Billion KRW | -233.91% |
| 2019 FY | 14.67 Billion KRW | 3387.61% |
| 2019 Q4 | 3.75 Billion KRW | -28.24% |
| 2019 Q3 | 5.22 Billion KRW | -62.53% |
| 2019 Q2 | 13.95 Billion KRW | 269.03% |
| 2019 Q1 | -8.25 Billion KRW | -10.61% |
| 2018 Q4 | -7.46 Billion KRW | -194.66% |
| 2018 FY | 420.84 Million KRW | 0.0% |
| 2018 Q3 | 7.88 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 12.87 Billion KRW | -73.395% |
| Green Cross Holdings Corporation | -54.13 Billion KRW | 141.225% |
| Green Cross Holdings Corporation | -26.63 Billion KRW | 183.801% |
| Pharmicell Co., Ltd. | 3.57 Billion KRW | -523.751% |
| Green Cross Corporation | -26.63 Billion KRW | 183.801% |
| GeneOne Life Science, Inc. | -77.76 Billion KRW | 128.698% |
| Celltrion, Inc. | 535.64 Billion KRW | 95.834% |
| Samsung Biologics Co.,Ltd. | 857.69 Billion KRW | 97.398% |
| SK Biopharmaceuticals Co., Ltd. | -32.88 Billion KRW | 167.87% |
| Prestige BioPharma Limited | -32.92 Billion KRW | 167.791% |